API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/asco-2022--ascentage-pharma-releases-updated-results-demonstrating-the-therapeutic-potential-of-alrizomadlin-apg-115-plus-pembrolizumab-in-patients-with-solid-tumors-who-progressed-on-immunotherapies-301562392.html
https://www.prnewswire.com/news-releases/ascentage-pharmas-mdm2-p53-inhibitor-alrizomadlin-apg-115-granted-rare-pediatric-disease-designation-by-the-us-fda-for-the-treatment-of-neuroblastoma-301507249.html